Palatin Technologies (PTN) risk factors, FY2025 10-K

Risks Related to Our Financial Results and Need for Financing

1. 01Our management has determined that there is substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing
2. 02We have a history of substantial net losses, including a net loss of $17.3 million for the year ended June 30, 2025. We expect to incur substantial net losses over the next few years, and we may never achieve or maintain profitability45% rewritten
3. 03We expect to incur significant expenses as we continue our development of MC1R and MCR products. These expenses, among other things, have had and will continue to have an adverse effect on our stockholders’ equity, total assets and working capital58% rewritten
4. 04We will need additional funding, including funding to complete clinical trials for our product candidates other than Vyleesi, which may not be available on acceptable terms, if at all
5. 05We have a limited operating history upon which to base an investment decision
6. 06If we are unable to obtain regulatory approval of any of our product candidates, to successfully commercialize any products for which we receive regulatory approval or to obtain additional capital, we may not be able to recover our investment in our development efforts
7. 07our ability to develop, in-license or acquire additional product candidates or commercial-stage products that we believe can be successfully developed and commercialized
8. 08Raising additional capital may cause dilution to existing stockholders, restrict our operations, or require us to relinquish rights

Risks Related to Our Business, Strategy, and Industry

1. 09The commercial success of Vyleesi for HSDD is a component of our corporate strategy, but we may not receive significant milestone payments under our purchase agreement with Cosette
2. 10a continued acceptable safety profile and efficacy of Vyleesi for HSDD or any future product candidates following approval
3. 11The commercial success of peptides assigned to Boehringer Ingelheim is a component of our corporate strategy, but we may not receive significant milestone payments under our agreement with Boehringer IngelheimNew
4. 12the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments; andNew
5. 13Ongoing military conflict could cause geopolitical instability, economic uncertainty, financial markets volatility and capital markets disruption, which may adversely affect our revenue, financial condition, or results of operations
6. 14the availability of sufficient capital to sustain operations and clinical trials
7. 15If clinical trials for our product candidates are prolonged or delayed, we may be unable to commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any revenue from potential product sales
8. 16difficulty in maintaining contact with subjects during or after treatment, which may result in incomplete data
9. 17We may not be able to secure and maintain relationships with research institutions and other organizations to conduct our clinical trials
10. 18Even if our product candidates receive regulatory approval, they may never achieve market acceptance, in which case our business, financial condition and results of operations will be materially adversely affected
11. 19Even if our product candidates receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States
12. 20our reputation in the marketplace may suffer resulting in a significant drop in the sales of such products
13. 21We may not be able to keep up with the rapid technological change in the biotechnology and pharmaceutical industries, which could make any future approved products obsolete and reduce our revenue
14. 22Competing products and technologies may make our proposed products noncompetitive
15. 23We rely on third parties over whom we have no control to conduct preclinical studies, clinical trials and other research for our product candidates and their failure to timely perform their obligations could significantly harm our product development
16. 24Production and supply of our product candidates depend on contract manufacturers over whom we have no control, with the risk that we may not have adequate supplies of our product candidates or products
17. 25If we are unable to establish sales and marketing capabilities within our organization or enter into and maintain agreements with third parties to market and sell our product candidates, we may be unable to generate product revenue
18. 26We may need to hire additional employees in order to commercialize our product candidates in the future. Any inability to manage future growth could harm our ability to commercialize our product candidates, increase our costs and adversely impact our ability to compete effectively
19. 27Our ability to achieve revenues from the sale of our products will depend, in part, on our ability to obtain adequate reimbursement from private insurers and other healthcare payers
20. 28Even if we receive regulatory approval for our products in Europe, we may not be able to secure adequate pricing and reimbursement in Europe for us or any strategic partner to achieve profitability
21. 29We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits
22. 30Our internal computer systems, or those of our third-party contractors or consultants, may fail or suffer security breaches, that could result in a material disruption of our product development programs
23. 31We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers
24. 32We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties
25. 33We are highly dependent on our management team, senior staff professionals and third-party contractors and consultants, and the loss of their services could materially adversely affect our business

Risks Related to Government Regulation

1. 34Both before and after marketing approval, our product candidates are subject to ongoing regulatory requirements and, if we fail to comply with these continuing requirements, we could be subject to a variety of sanctions and the sale of any approved commercial products could be suspended
2. 35refusal to approve pending applications for marketing approval of new product candidates
3. 36In addition, varying interpretations of the data obtained for preclinical and clinical testing could delay, limit or prevent regulatory approval of a product candidate. Even if we submit an application to the FDA for marketing approval of a product candidate, it may not result in marketing approval from the FDA
4. 37The regulatory approval process is lengthy, expensive and uncertain, and may prevent us from obtaining the approvals that we require
5. 38compliance with post-approval commitments and requirements
6. 39Legislative or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of any future product candidates and to produce, market and distribute our products after clearance or approval is obtained
7. 40restrict or eliminate our ability to settle any patent litigation we may bring against potential generic competitors
8. 41Changes in healthcare policy could adversely affect our business

Risks Related to Our Intellectual Property

1. 42If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish
2. 43whether we will need to initiate litigation or administrative proceedings, which may be costly whether we win or lose
3. 44We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time-consuming
4. 45An adverse determination of any litigation or other proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing
5. 46If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed
6. 47Our patent applications and the enforcement or defense of our issued patents may be impacted by the application of or changes in U.S. and foreign standards
7. 48We may not be able to protect our intellectual property rights throughout the world
8. 49If we are unable to keep our trade secrets confidential, our technologies and other proprietary information may be used by others to compete against us

Risks Related to the Ownership of Our Common Stock

1. 50Our stock price is volatile and may fluctuate in a way that is disproportionate to our operating performance and we expect it to remain volatile, which could limit investors’ ability to sell stock at a profit
2. 51the other factors described in this “Risk Factors” section
3. 52If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline
4. 53Holders of our Series A Preferred Stock and Series D Preferred Stock may have interests different from our common stockholders
5. 54Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be our stockholders’ sole source of gains
6. 55Anti-takeover provisions of Delaware law and our charter documents may make potential acquisitions more difficult and could result in the entrenchment of management
7. 56Our charter authorizes us to issue up to 10,000,000 shares of preferred stock and to determine the terms of those shares of stock without any further action by our stockholders. If we exercise this right, it could be more difficult for a third party to acquire a majority of our outstanding voting stock
8. 57We are a smaller reporting company and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors69% rewritten
9. 5865,433 shares of common stock available for future issuance under our 2011 Stock Incentive Plan
10. 59Our common stock has been suspended from trading on the NYSE American. If we fail to regain compliance with the NYSE American listing standards, our common stock may be delisted from the NYSE American99% rewritten
11. 60a decreased ability to issue additional securities or obtain additional financing in the futureNew